Provera Dosing for Menstrual Suppression
For menstrual suppression, Provera (medroxyprogesterone acetate) should be dosed at 20 mg orally daily when used continuously for prevention of menstrual bleeding, or 5–10 mg daily for 5–10 days when used cyclically to treat abnormal uterine bleeding. 1
Continuous Regimen for Menstrual Suppression
The recommended dose for continuous menstrual suppression is 20 mg orally daily, based on institutional protocols developed for patients requiring prevention of uterine bleeding during intensive chemotherapy. 2
This continuous regimen is typically combined with leuprolide acetate (a 3-month formulation) for maximal suppression in high-risk settings. 2
Continuous daily dosing at 5–10 mg may also achieve amenorrhea over time, with higher doses (10 mg daily) producing more consistent endometrial atrophy and increased rates of amenorrhea within 12–24 months. 3
Cyclic Regimen for Abnormal Uterine Bleeding
For treatment of abnormal uterine bleeding, the FDA-approved dosing is 5–10 mg daily for 5–10 days, beginning on the calculated 16th or 21st day of the menstrual cycle. 1
Progestin withdrawal bleeding typically occurs within 3–7 days after discontinuing therapy. 1
Patients with recurrent episodes of abnormal bleeding may benefit from planned menstrual cycling with this regimen. 1
Dosing for Endometrial Protection in Postmenopausal Women
When combined with conjugated estrogens (0.625 mg daily) in postmenopausal women with a uterus, Provera is dosed at 5–10 mg daily for 12–14 consecutive days per month to reduce endometrial hyperplasia risk. 1
This regimen may begin on day 1 or day 16 of the cycle. 1
Patients should be started at the lowest effective dose, though the precise lowest effective dose has not been definitively established. 1
Important Clinical Considerations
Breakthrough Bleeding Management
If breakthrough bleeding occurs during continuous use, NSAIDs (e.g., ibuprofen 400–600 mg three times daily) for 5–7 days are first-line treatment while continuing Provera. 4
Before treating persistent bleeding, exclude pregnancy, sexually transmitted infections, thyroid disorders, medication interactions, and new uterine pathology (polyps, fibroids). 5, 4
For heavy or prolonged bleeding despite NSAIDs, consider a short course (10–20 days) of combined oral contraceptives or estrogen therapy. 4
Expected Bleeding Patterns
Menstrual disturbances are common with all progestogen-only methods, including irregular spotting, breakthrough bleeding, and eventual amenorrhea with prolonged use. 1, 6
Amenorrhea becomes increasingly common with continued use; approximately 50% of users achieve amenorrhea or oligomenorrhea within 2 years when using depot formulations. 4
Counseling about expected bleeding patterns before initiation improves continuation rates and patient satisfaction. 4, 6
Dose-Response Relationship
Higher doses (10 mg daily) produce more consistent endometrial atrophy and faster onset of amenorrhea compared to lower doses (2.5–5 mg daily). 3
In a dose-ranging study, 10 mg daily achieved amenorrhea in 90% of patients by 12 months and 100% by 24 months, compared to persistent proliferative endometrium in some patients receiving 2.5 mg daily. 3
However, even high-dose oral medroxyprogesterone acetate may produce suboptimal endometrial responses compared to other progestogens, with variable and inconsistent secretory changes. 7
Common Pitfalls to Avoid
Do not use Provera as a test for pregnancy; always confirm non-pregnant status before initiating therapy, as there may be an increased risk of minor birth defects if taken during the first 4 months of pregnancy. 1
Do not discontinue therapy prematurely for breakthrough bleeding during the first 3–6 months, as this is expected and typically resolves with continued use. 4
Do not prescribe copper IUDs for menstrual suppression, as they exacerbate menstrual bleeding rather than reduce it. 4
Be aware that prolonged use (>4 years) or initiation at age >31 years may be associated with increased meningioma risk, though the absolute risk remains low (number needed to harm = 3020 for oral formulation). 8
Monitor for weight gain, which is a common side effect that may affect continuation rates. 1, 6